Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients Please visit their website for more information.
*Proprietary Buy Sell Volume Indicator
| Revenue: $0M |
| Revenue Growth (YOY): nan% |
| Profit (% of Rev): nan% |
| Income (% of Rev): -inf% |
| Income Growth (YOY): 83.33% |
| Operating Income: $-82M |
| Operating Cash Flow: $-70M |
| Operating Cash Flow Growth (YoY): 41.64% |
| Annual Dividend Yield: 0.00% |
| Total Assets: $818M |
| Total Liabilities: $79M |
| Cash & Equivalent: $316M |
| Total Debt: $1M |
| Debt/Equity: 0.00 |
| Quick Ratio: 17.25 |
| Current Ratio: 17.25 |
| Price/Book: 2.70 |
| Price/Earnings: -6.85 |
| EBITDA: $-82M |
| EPS: -1.05 |
Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Sell.
TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.
Contact @ support@theoryofstocks.com
© 2024 Stock Articles. All rights reserved.